The company posted a net income of $207 million in the second quarter of 2008, an increase of 11% compared to $186 million in the second quarter of 2007.
Second quarter 2008 diluted earnings per share (EPS) was $0.70, an increase of 30% from $0.54 reported in the second quarter of 2007.
James Mullen, Biogen Idec’s CEO, said: “Our prospects for growth remain strong. Tysabri sales nearly tripled compared to the same period last year, our core products continue to grow, our pipeline is overflowing, and our revenues have grown more than 25% year-over-year for three consecutive quarters.
“Given the strong momentum underway, we are raising our full-year guidance and setting an aspirational goal of generating a record $4 billion in revenues this year.”